|
ADAG
|
Adagene Inc.
|
US
|
NASDAQ
|
|
ADAP
|
Adaptimmune Therapeutics plc
|
US
|
NASDAQ
|
|
AVRO
|
AVROBIO, Inc.
|
US
|
NASDAQ
|
|
BLCM
|
Bellicum Pharmaceuticals, Inc.
|
US
|
NASDAQ
|
|
BMRN
|
BioMarin Pharmaceutical Inc.
|
US
|
NASDAQ
|
|
CDMO
|
Avid Bioservices, Inc.
|
US
|
NASDAQ
|
|
CPRX
|
Catalyst Pharmaceutical Partners, Inc.
|
US
|
NASDAQ
|
|
DTIL
|
Precision BioSciences, Inc.
|
US
|
NASDAQ
|
|
ENLV
|
Enlivex Therapeutics Ltd.
|
US
|
NASDAQ
|
|
FBIOP
|
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
US
|
NASDAQ
|
|
GRTS
|
Gritstone Oncology, Inc.
|
US
|
NASDAQ
|
|
IBRX
|
ImmunityBio, Inc.
|
US
|
NASDAQ
|
|
IMCR
|
Immunocore Holdings plc
|
US
|
NASDAQ
|
|
IMNN
|
Imunon, Inc.
|
US
|
NASDAQ
|
|
IMTX
|
Immatics N.V.
|
US
|
NASDAQ
|
|
IMV
|
IMV Inc.
|
US
|
NASDAQ
|
|
INDP
|
Indaptus Therapeutics, Inc.
|
US
|
NASDAQ
|
|
MBIO
|
Mustang Bio, Inc.
|
US
|
NASDAQ
|
|
MEIP
|
MEI Pharma, Inc.
|
US
|
NASDAQ
|
|
MRKR
|
Marker Therapeutics, Inc.
|
US
|
NASDAQ
|